Lyell Immunopharma, Inc. announced that on October 23, 2021, the compensation committee of the board of directors approved the promotion of Stephen Hill, the Company?s Chief Technical Operations Officer, to the position of Chief Operating Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal. Such promotion will be effective on November 1, 2021. Mr. Hill, age 51, has served as the Company?s Chief Technical Operations Officer since joining the Company in June 2019. Prior to joining the Company, he was Senior Vice President, Head of Global Biologics Operations at AstraZeneca plc.